Overview

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-12
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Phase:
PHASE1
Details
Lead Sponsor:
Forte Biosciences, Inc.